Press releases
- METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
- TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany
- Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
- Novocure Reports First Quarter 2024 Financial Results
- Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
- Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
- Novocure to Report First Quarter 2024 Financial Results
- Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
- METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
More ▼
Key statistics
As of last trade, Novocure Ltd (038:STU) traded at 19.75, 93.11% above the 52 week low of 10.23 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 19.75 |
---|---|
High | 19.75 |
Low | 19.75 |
Bid | 19.29 |
Offer | 20.61 |
Previous close | 20.17 |
Average volume | 1.25 |
---|---|
Shares outstanding | 107.61m |
Free float | 97.64m |
P/E (TTM) | -- |
Market cap | 2.30bn USD |
EPS (TTM) | -1.81 USD |
Data delayed at least 15 minutes, as of Jun 14 2024.
More ▼